| Reference number: | 01KA1701 |
| Funding amount: | 3.211.620 EUR |
| Funding Period: | 2017 - 2022 |
| Project leader: | Prof. Dr. Michael Hölscher |
| Address: |
Ludwig-Maximilians-Universität München, Klinikum - Abt. für Infektions- und Tropenmedizin Leopoldstr. 5 80802 München |
The aim is to evaluate the clinical tolerability and bactericidal effects of two new drugs (Q203 and BTZ043) and 4 new drug combinations (isoniazid (H), high dose rifampicin (Rhigh), pyrazinamide (Z), ethambutol (E), HRhighZhighE, HRZQ (KUM) in the above-mentioned clinical trials assumes the sponsorship responsibility, which means that KUM is the most effective and effective method for the treatment of rifampicin (50 mg / kg body weight) Is instrumental in the development of the study protocol, the monitoring of GCP-compliant study performance, and data analysis.
